| 5263- | 3BP, | CET, | 3-Bromopyruvate overcomes cetuximab resistance in human colorectal cancer cells by inducing autophagy-dependent ferroptosis |
| - | in-vitro, | CRC, | DLD1 | - | NA, | NA, | HCT116 |
| 5257- | 3BP, | Tumor Energy Metabolism and Potential of 3-Bromopyruvate as an Inhibitor of Aerobic Glycolysis: Implications in Tumor Treatment |
| - | Review, | Var, | NA |
| 5258- | 3BP, | 3-bromopyruvate: Targets and outcomes |
| - | Review, | Var, | NA |
| 5259- | 3BP, | Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP |
| - | in-vivo, | HCC, | NA |
| 5260- | 3BP, | Systemic Delivery of Microencapsulated 3-Bromopyruvate for the Therapy of Pancreatic Cancer |
| - | in-vivo, | PC, | NA |
| 5261- | 3BP, | The cytotoxicity of 3-bromopyruvate in breast cancer cells depends on extracellular pH |
| - | in-vitro, | BC, | NA |
| 5269- | 3BP, | The anti-metabolite KAT/3BP has in vitro and in vivo anti-tumor activity in lymphoma models. |
| - | in-vitro, | HCC, | NA |
| 5264- | 3BP, | Candidate cancer drug suspected after death of three patients at an alternative medicine clinic |
| - | Review, | Var, | NA |
| 5265- | 3BP, | KAT/3BP: A Metabolism-Targeting Agent with Single and Combination Activity in Aggressive B-Cell Lymphomas |
| - | Review, | lymphoma, | NA |
| 5266- | 3BP, | 3-bromopyruvate-based agent KAT-101 |
| - | Review, | Var, | NA |
| 5267- | 3BP, | Targeting Energy Metabolism in Cancer Treatment |
| - | Review, | Var, | NA |
| 5270- | 5-ALA, | PDT, | 5-Aminolevulinic Acid as a Theranostic Agent for Tumor Fluorescence Imaging and Photodynamic Therapy |
| - | Review, | Var, | NA |
| 3453- | 5-ALA, | The heme precursor 5-aminolevulinic acid disrupts the Warburg effect in tumor cells and induces caspase-dependent apoptosis |
| - | in-vitro, | Lung, | A549 |
| 3452- | 5-ALA, | 5-ALA Is a Potent Lactate Dehydrogenase Inhibitor but Not a Substrate: Implications for Cell Glycolysis and New Avenues in 5-ALA-Mediated Anticancer Action |
| - | in-vitro, | GBM, | T98G | - | in-vitro, | GBM, | LN-18 | - | in-vitro, | GBM, | U87MG |
| - | in-vitro, | CRC, | NA |
| 3537- | 5-HTP, | 5-Hydroxytryptophan: a clinically-effective serotonin precursor |
| - | Review, | NA, | NA |
| 3538- | 5-HTP, | Oral Administration of 5-Hydroxytryptophan Restores Gut Microbiota Dysbiosis in a Mouse Model of Depression |
| - | in-vivo, | Nor, | NA |
| 5308- | 5-HTP, | The Relationship Between Serotonin and 5-HTP |
| - | Review, | Nor, | NA |
| 5309- | 5-HTP, | Effects of Carbidopa on the Cerebral Accumulation of Exogenous L-5-Hydroxytryptophan in Mice |
| 5302- | 5-HTP, | Hippocampal ischaemia from accidental 5-Hydroxytryptophan (5-HTP) overdose case report |
| - | Case Report, | Nor, | NA |
| 5310- | 5-HTP, | 5-Hydroxytryptophan toxicity successfully treated by haemodialysis in a dog |
| - | Case Report, | Nor, | NA |
| 5311- | 5-HTP, | A case report of suspected serotonin syndrome following administration of fentanyl |
| 5303- | 5-HTP, | 5-HTP shows early promise for cognitive support and in seniors: Singapore study |
| - | Trial, | AD, | NA |
| 5298- | 5-HTP, | Pharmacology of rising oral doses of 5-hydroxytryptophan with carbidopa |
| - | Human, | AD, | NA |
| 5297- | 5-HTP, | Targeting 5-HT Is a Potential Therapeutic Strategy for Neurodegenerative Diseases |
| - | in-vivo, | AD, | NA | - | in-vivo, | Park, | NA |
| 5296- | 5-HTP, | Serotonergic Regulation in Alzheimer’s Disease |
| - | Review, | AD, | NA |
| 5295- | 5-HTP, | Safety of 5-hydroxy-L-tryptophan |
| - | in-vivo, | Nor, | NA |
| 5294- | 5-HTP, | Eosinophilia-myalgia syndrome case-associated contaminants in commercially available 5-hydroxytryptophan |
| - | in-vivo, | Nor, | NA |
| 5293- | 5-HTP, | The Role of Tryptophan Metabolism in Alzheimer’s Disease |
| - | in-vivo, | AD, | NA |
| 5292- | 5-HTP, | Past, present, and future of serotonin-targeting therapeutics for Alzheimer’s disease: Perspectives from DNA methylation |
| - | Review, | AD, | NA |
| 5291- | 5-HTP, | Kinetics of l-5-hydroxytryptophan in healthy subjects |
| - | in-vivo, | Nor, | NA |
| 5290- | 5-HTP, | Placebo-controlled comparison of three dose-regimens of 5-hydroxytryptophan challenge test in healthy volunteers |
| - | in-vivo, | Nor, | NA |
| 5289- | 5-HTP, | 5-Hydroxytryptophan (5-HTP): Natural Occurrence, Analysis, Biosynthesis, Biotechnology, Physiology and Toxicology |
| - | Review, | AD, | NA | - | Review, | Arthritis, | NA |
| 5288- | 5-HTP, | The Impact of 5-Hydroxytryptophan Supplementation on Cognitive Function and Mood in Singapore Older Adults: A Randomized Controlled Trial |
| - | Trial, | AD, | NA |
| 5304- | 5-HTP, | Serotoninergic System in Dementia of the Alzheimer Type |
| - | Human, | AD, | NA |
| 5306- | 5-HTP, | Tryptophan-enriched diet or 5-hydroxytryptophan supplementation given in a randomized controlled trial impacts social cognition on a neural and behavioral level |
| - | Trial, | AD, | NA |
| 5301- | 5-HTP, | Eosinophilia-myalgia syndrome presenting with overlapping features of eosinophilic fasciitis and sarcoidal granulomas |
| - | Case Report, | NA, | NA |
| 5300- | 5-HTP, | The Serotonin Syndrome: From Molecular Mechanisms to Clinical Practice |
| - | Review, | Nor, | NA |
| 5299- | 5-HTP, | Serotonin Syndrome from 5-Hydroxytryptophan Supplement Ingestion in a 9-Month-Old Labrador Retriever |
| - | Case Report, | AD, | NA |
| 5307- | 5-HTP, | 5-Hydroxytryptophan toxicosis in dogs: 1989-1999 |
| - | Case Report, | Nor, | NA |
| 5305- | 5-HTP, | An Investigation of the Cause of the Eosinophilia–Myalgia Syndrome Associated with Tryptophan Use |
| - | Review, | Nor, | NA |
| 3940- | 5HT, | Role of serotonin in Alzheimer's disease: a new therapeutic target? |
| - | Review, | AD, | NA |
| 3941- | 5HT, | dietMed, | VitB12, | FA, | VitC | Nutrition strategies that improve cognitive function |
| - | Review, | AD, | NA |
| 5312- | acet, | Analgesic Effect of Acetaminophen: A Review of Known and Novel Mechanisms of Action |
| 5313- | acet, | Pharmacological hypotheses: Is acetaminophen selective in its cyclooxygenase inhibition? |
| - | Review, | Nor, | NA |
| 5314- | acetaz, | Carbonic Anhydrase Inhibitors Targeting Metabolism and Tumor Microenvironment |
| - | Review, | Var, | NA |
| 1094- | ACNs, | Anthocyanidins inhibit epithelial-mesenchymal transition through a TGF-β/Smad2 signaling pathway in glioblastoma cells: Anthocyanidins inhibit TGF-β-mediated EMT. |
| - | in-vitro, | GBM, | U87MG |
| 1161- | ACNs, | immuno, | Bilberry anthocyanin extracts enhance anti-PD-L1 efficiency by modulating gut microbiota |
| - | in-vivo, | Colon, | MC38 |
| - | in-vivo, | AD, | NA |
| 3968- | ACNs, | Enhanced Neuronal Activation with Blueberry Supplementation in Mild Cognitive Impairment |
| - | Human, | AD, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid